Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
作者
David E. Gerber,Mark A. Socinski,Joel W. Neal,Heather A. Wakelee,Keisuke Shirai,Lecia Van Dam Sequist,Rachel Pam Greenerger Rosovsky,Rogério Lilenbaum,Bruno R. Bastos,C. Huang,M.L. Johnson,P.J. Hasketh,Deepa Suresh Subramaniam,F. Chai,Julia Kazakin,Brian E. Schwartz,Joan H. Schiller,Julie Renee Brahmer